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Background. There are some patients with SCLC that are diagnosed in the operating room by cryosection and surgeons had to
perform surgical resection for these patients. The aim of this study is to compare the eﬀective of pneumonectomy with lobectomy
for SCLC. Methods. A retrospective study was undertaken in 75 patients with SCLC that were diagnosed by cryosection during
surgery. 31 of them underwent pneumonectomy, 44 underwent lobectomy. Local recurrence rate and survival rate according
to surgical procedures and cancer stages were analyzed. Results. There was signiﬁcant diﬀerence in the overall survival rate
between lobectomy and pneumonectomy groups (P = 0.044). For patients with stage II SCLC, the overall survival rate after
pneumonectomy was signiﬁcantly better than after lobectomy (P = 0.028). No signiﬁcant diﬀerence in overall survival rate was
found between the two surgical groups in patients with stage III SCLC (P = 0.933). The local recurrence rate in lobectomy group
was signiﬁcant higher that in pneumonectomy group (P = 0.0017). Conclusions. SCLC was responsive to surgical therapy. When
surgeons have to select an appropriate method of operation for patients with SCLC during surgery, pneumonectomy may be the
right choice for these patients. Pneumonectomy can result in signiﬁcantly better local control and higher survival rate compare
with lobectomy.
1.Background
According to World Health Organization (WHO) statistics,
more than 1 million cases of lung cancer are diagnosed
annually around the world. The incidence of small cell lung
cancer (SCLC) was about 20–25% of all newly diagnosed
lungcancers[1].SCLCisconsidereddistinctfromotherlung
cancers, because of their clinical and biologic characteristics.
It exhibits aggressive behavior, with rapid growth and early
spread. SCLC seems sensitive to both chemotherapy and
radiotherapy, but the overall 5-year survival rate is still
poor despite the sensitivity [2]. Although the eﬃcacy of
surgery for SCLC is controversial, surgical excision is still
believed a curative treatment. In fact, some patients with
SCLC were diagnosed in the operating room by cryosec-
tion. For these patients the surgeon had to choose proper
surgical procedure. We found some patients with SCLC
who underwent pneumonectomy experienced long-term
survival. We supposed that pneumonectomy might achieve
complete resection and conferred a survival advantage for
these patients. This study reviewed the records of 75 patients
with SCLC diagnosed by intraoperative cryosection and
compared the therapeutic eﬃcacy of pneumonectomy and
lobectomy on patients with SCLC.
2. Methods
FromJanuary1982 toDecember2010, therewere85patients
did not that a conﬁrmed diagnosis of SCLC before resection
and underwent surgery at the Department of Thoracic
Surgery of Chongqing Cancer Hospital & Institute. For
51 of the 85 patients (60%), histological or cytological
diagnosiswasnotobtainedpreoperatively.Fortheremaining
34 patients, the preoperative diagnosis of adenocarcinoma
was in 11 cases, bronchioloalveolar carcinoma in 11 cases,
squamous cell carcinoma in 12 cases.
2 patients had an incomplete resection, and 1 patient had
unresectable disease. 6 patients had the pathologic subtype
with combined histology tumor (mixtures of SCLC with2 ISRN Surgery
non-SCLC components). 1 patient died of perioperative
complications. Thus 75 patients with SCLC were in this
study. This study was approved by the Ethics Committee of
Chongqing Cancer Hospital & Institute, China.
There were 69 men and 6 women, with the median age of
56 years (range 41–71 years). The preoperative assessments
included chest roentgenography, computed tomography of
thechest,externalultrasonographyoftheabdomenandbone
scintigraphy. Magnetic resonance imaging of the brain was
used in 51 patients. In this study, 61 patients underwent
bronchoscopy and 23 patients underwent mediastinoscopy
without deﬁnite diagnosis of SCLC. 56 patients get PET-CT
(Positron emission tomography-computed tomography).
Because all the patients in this study had no pathological
diagnosis of SCLC preoperatively, induction chemotherapy
was not performed.
All operations were performed with curative intent and
every patient underwent mediastinal lymph node resection.
Pathologic staging was undertaken according to the 7th
edition of the AJCC staging system of lung cancer. All
these patients were referred for consideration of adjuvant
chemotherapy and prophylactic cranial irradiation (PCI).
The postoperative chemotherapy was performed with the PE
regimen that is etoposide and either cisplatin or carboplatin.
Four to six cycles of chemotherapy were performed if the
patient’sconditionaftersurgerywaswelltolerableagainstthe
treatment. 8 patients were not treated with PCI and 5 of the
8 patients were not treated with adjuvant chemotherapy.
2.1. Followup. Following hospital discharge, patients with
SCLC were regularly monitored in the outpatient depart-
ment at intervals of 1 month for the ﬁrst 1 year, 3 months for
the next 2 years, and every 6 months thereafter. All patients
in this study underwent a clinical evaluation that included
chestradiography,externalultrasonographyoftheabdomen,
computed tomography (CT) scans of the thorax, and bone
emission computed tomography (ECT) scanning at least
once half year. Local recurrence was deﬁned as recurrence
that occurred within the ipsilateral hemithorax including the
mediastinum.
2.2. Statistical Analysis. Survival was deﬁned as the interval
between date of surgery and date of death or last fol-
lowup. Survival rates were calculated using the Kaplan-Meier
method and the diﬀerences were compared using the log-
rank test. Comparisons of continuous and dichotomous
variablesbetweengroupswereperformedwiththeStudentt-
test and χ2 tests, respectively. All analyses were accomplished
with SPSS 13 statistical package.
3. Results
3.1. Surgery. 31 patients underwent pneumonectomy (in-
cluding 7 right and 24 left pneumonectomies). 44 patients
underwent lobectomy (including 12 patients underwent
sleeve resection). The lobectomy procedures included 12
right upper lobectomies, 1 middle lobectomy, 2 right upper
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Figure 1: Survival curves according to surgical procedures. The 5-
year survival rate for patients with SCLC was 16.1% by lobectomy,
24.0% by pneumonectomy. There was signiﬁcant diﬀerence in the
overall survival rate between the two groups (P = 0.044).
and middle lobectomies, 2 middle and right lower lobec-
tomies, 9 right lower lobectomies, 10 left upper lobectomies,
and 8 left lower lobectomies. The patients were divided into
two: groups pneumonectomy group (n = 31) and lobectomy
group (n = 44).
3.2. Characteristics of the Patients. The clinical and patho-
logic characteristics of the two group patients are presented
in Table 1. There were no statistical diﬀerences between the
two groups regarding age, sex, and adjuvant therapy. The
pathologic stage of the lobectomy group was stage I in 2,
stage II in 29, and stage III in 13 patients. The pathologic
stage of pneumonectomy group was stage II in 24 and stage
III in 7 patients. There were no patients with stage I in
pneumonectomy group. Statistic analysis showed that there
was no signiﬁcant diﬀerence in distribution of pathologic
stage between the two groups (P = 0.249).
3.3. Survival Rate of the Patients and Local Recurrence with
SCLC. The median survival time and 5-year survival rate
for entire cohort were 22 months and 20.34%. They were
27 months and 26.2% for stage II, 18 months and 0.0% for
stageIII.Themediansurvivaltimeand5-yearsurvivalrateof
patientswithSCLCwere20monthsand11.1%bylobectomy,
28 months and 24.0% by pneumonectomy (Table 2). There
was signiﬁcant diﬀerence in the overall survival rate between
the two surgical groups (P = 0.044; Figure 1).
The median survival time and 5-year survival rate of
patients with stage II SCLC were 22 months and 16.7%
in lobectomy group, 30 months and 31.6% in the pneu-
monectomy group. For patients with stage II SCLC, the
overall survival rate after pneumonectomy was signiﬁcantly
better than after lobectomy (P = 0.028, Figure 2). For
patients with stage III SCLC, the median survival time
was 16 months in lobectomy group and 18 months inISRN Surgery 3
Table 1: Characteristics of the patients with lobectomy and pneumonectomy.
Characteristic Lobectomy (n = 44) Pneumonectomy
(n = 31) P value
Age mean ± SD (years) 58.5 ±18.45 7 .9 ±17.8 0.8609
Gender
Male 40 29 0.6782
Female 4 2
Adjuvant therapy
Chemotherapy alone 1 2 0.3631
Chemotherapy plus PCI 43 29
Pathologic stage
I3 0
II 31 24 0.3272
III 10 7
Table 2: Comparison of Local recurrence and survival rate.
Lobectomy Pneumonectomy P
All stage
Median survival time (CI) 20 (15.83–24.16) n = 44 28 (21.52–34.48) n = 31
5-year survival rate 11.1% 24.0% 0.044
Local recurrence rate 59.1% (26/44) 22.6% (7/31) 0.0017
Stage II
Median survival time (CI) 21 (17.03–24.97) n = 31 30 (18.48–41.52) n = 24
5-year survival rate 16.7% 31.6% 0.028
Local recurrence rate 61.3% (19/31) 20.8% (5/24) 0.0027
Stage III
Median survival time (CI) 16 (11.35–20.65) n = 10 18 (5.16–30.83) n = 7
5-year survival rate 0 0 0.933
Local recurrence rate 60% (6/10) 28.6% (2/7) 0.3348
CI: 95% conﬁdence interval.
pneumonectomy group respectively. There was no patient
with stage III SCLC who survived for more than 5 years in
this study. No signiﬁcant diﬀerence in overall survival rate
was found between lobectomy group and pneumonectomy
group in patients with stage III SCLC (P = 0.933, Figure 3).
The local recurrence rate comparison of two surgical
procedures was showed in Table 2. The local recurrence
rate were 59.1% (26/44) in lobectomy group, 22.6% (7/31)
in pneumonectomy group, there was statistically signiﬁcant
diﬀerence in local recurrence rate between the two groups
(P = 0.0017). By stages, there was statistically signiﬁcant
diﬀerence of local recurrence rate between the two surgical
groups in stage II SCLC (P = 0.002), but no signiﬁcant
diﬀerenceoflocalrecurrenceratewasfoundbetweenthetwo
groups in stage III SCLC (P = 0.3348).
In our study, the patients with sleeve resection were
included into lobectomy group, because there was no
signiﬁcant diﬀerence in overall survival rate between the
patients who underwent general lobectomy and these who
underwent sleeve resection lobectomy (P = 0.877, Figure 4).
4. Discussion
The eﬃcacy of surgery in SCLC is controversial. About
30 years ago, British Medical Research Council performed
a randomized trial about surgery versus radiotherapy for
SCLC. The result showed that surgery and radiotherapy
were equally ineﬀective in limited stage SCLC [2–4]. This
result has been widely cited as evidence to prove that
surgical treatment to SCLC is ineﬀective. But proponents
of surgery argue that there were some limitations in that
randomized trial. CT scanning and mediastinoscopy were
unavailable at that time. The patients recruited in that trial
were not currently suitable for surgery, complete resection
wasonlyachievedin34(48%)patientsand37(52%)patients
underwent exploratory thoracotomy only.
With the advent of new diagnostic tools, such as spiral
computed tomography and positron emission tomogra-
phy, limited disease can be more readily identiﬁed and
adequately staged preoperatively. Some clinicians believed
that good results can be achieved in selected patients with4 ISRN Surgery
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Figure 2: Survival curves of patients with stage II SCLC according
to surgical procedures. The 5-year survival rate of patients with
stage II SCLC was 16.7% in lobectomy group, 31.6% in the
pneumonectomy group. For patients with stage II SCLC, the overall
survival rate after pneumonectomy was signiﬁcantly better than
after lobectomy (P = 0.028).
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Figure3:SurvivalcurvesofpatientswithstagIIISCLCaccordingto
surgicalprocedures.Nosigniﬁcantdiﬀerenceinoverallsurvivalrate
wasfoundbetweenlobectomygroupandpneumonectomygroupin
patients with stage III SCLC.
complete resection [5, 6]. Moreover, with the platinum
agent, granulocyte-colony-stimulating factor, and serotonin-
antagonizing antiemetic agent becoming available, the
chemotherapeuticregimensforSCLChavebeenchanged[7–
10]. Recent studies reported that multimodality treatment
involving surgery achieved a good prognosis in SCLC
patients withlimited stagedisease,thussuggestedtheimpor-
tance of surgery with a curative intent [11, 12].
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Figure 4: Survival curves of patients according to surgery of
sleeve resection lobectomy and lobectomy. There was no signiﬁcant
diﬀerence in overall survival rate between the patients who
underwent general lobectomy and these who underwent sleeve
resection lobectomy (P = 0.877).
Althoughmanyresearchesconﬁrmedthatmultimodality
treatment including surgery and chemotherapy might repre-
sent an eﬀective form of treatment for limited SCLC, it was
generally accepted that surgical resection was appropriate
only for the patients with stage I SCLC [13, 14]. However,
stage of SCLC is usually underestimated preoperatively [2,
15]. Lymph node metastasis is often underestimated, and
occult mediastinal involvement might be missed even by
medistinoscopy. Eric Lim and his colleagues reported 59
patients with stage I to III SCLC who underwent lung
resection with nodal dissection and showed excellent overall
5-year survival of 52%. Their surgical series suggests that
good results can be achieved in selected patients with
complete resection throughout the spectrum of UICC stage I
to III [5].
Our study reviewed 75 patients that do not have con-
ﬁrmed diagnosis of SCLC preoperatively. The reason is
that there were no CT and bronchoscope in our institute
until 1989. So, not every patient in this group gets these
assessments even after 1989 because of economic reason.
Also some of these patients were misdiagnosed as NSCLC.
Their postoperative pathologic stages included stage I in 3
cases, stage II in 55 cases, and stage III in 17 cases. The
median survival time and postoperative 5-year survival rate
of patients with SCLC in our surgical series were 22 months
and 20.34%. These ﬁgures can be compared with the results
reported by Brock et al. [14] and are poorer than the result
reported by Inoue et al. [15].
Comparing the median survival time and survival rate of
two surgical procedures, we found that the median survival
time and 5-year survival rate by pneumonectomy were better
than those by lobectomy (28 months, 24.0% versus 20
months, 11.1%), and statistical analysis showed there was
signiﬁcant diﬀerence in overall survival rate between the twoISRN Surgery 5
groups (P = 0.044). Moreover, our study showed that for
patientswithstageIISCLC,thepostoperativeoverallsurvival
rates by pneumonectomy were signiﬁcantly better than by
lobectomy (P = 0.028). For patients with stage III SCLC,
there was no diﬀerence between the two surgical groups in
overall survival rates (P = 0.933).
We had examined 31 cases of pneumonectomy for
SCLC in this study. It was because we found that SCLC
usually originates in the lung’s large central airways, invades
the main bronchus and fuses with metastatic hilar lymph
nodes at presentation. The metastatic lymph nodes usually
involve interlobular lymph node and peribronchial lymph
nodes of neighboring lobe also. Lobectomy often leaves
these peribronchial lymph nodes in neighboring lobe. It
is even impossible to distinguish primary tumor from
lymph node metastasis during operation. Shepherd reported
that local control remains a problem, with one-third of
patients having recurrence only at the primary site. Failure
to achieve control at the primary site remains the single
most important obstacle to cure in patients with limited
SCLC [16]. We believe that pneumonectomy can achieve
complete resection of the neoplasm for SCLC rather than
lobectomy do. In this study, the local recurrence rate of
patients with SCLC was 59.1% (26/44) in lobectomy group,
and it was 22.6% (7/31) in pneumonectomy group. There
was signiﬁcant diﬀerence between the two groups in local
recurrence rate (P = 0.0017). The results indicate that
pneumonectomy can aﬀord better curability rates than
lobectomy.
5. Conclusion
Chemotherapy in combination with radiation therapy is the
mainstay of treatment for SCLC. But there are still some
patients with SCLC that are diagnosed intraoperatively. In
thisspeciﬁcsituation,thesurgeonmustselectanappropriate
method of operation to complete the operation for these
patients. In our study, we can easily draw the conclusion
that pneumonectomy can achieve complete resection and
reduce local recurrence rate of patients with SCLC. It can
result in better local control than lobectomy. The survival of
patients with SCLC after pneumonectomy is better than after
lobectomy.
Nevertheless, there were some limitations in this study
which should be noted. The patients in the two surgical
groups were not selected by randomization. In pneumonec-
tomy group, 70 years old was the upper limit age of
patients. Patients with pneumonectomy had healthy lung
function and strong heart. These factors may inﬂuence on
survival rate. Also the long-term complications of the two
surgical procedures were not analyzed in this study. We had
mediastinoscopy instrument after 2000: only 23 patients in
this study received mediastinoscopy. In recent 15 years, we
seldom performed surgery to patients with SCLC, because
we also think that surgical intervention in the management
of SCLC is not considered standard. So most of the cases in
this study were before 15 years ago.
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